Australia | May 16 2006
By Rudi Filapek-Vandyck
ABN Amro Morgans’ healthcare specialists Tanya Solomon and Scott Power report in their latest weekly sector update they recently met with Dan Segal, COO and director of The Brain Resource Company (BRC) – don’t look at us, we didn’t come up with the name!
Solomon and Power describe BRC as “a little known life science company which has developed benchmarks (biomarkers) which large pharmaceutical companies use in clinical trials with particular relevance to trials in depression, Alzheimers and ADHA”.
On its website, www.brainresource.com, the company presents itself as the only one of its kind delivering “objective, "evidence-based" reports of brain function to help make sense of the brain’s complexities”.
Last calendar year BRC generated $1.5m in revenue and both analysts report management expects to see similar revenue coming in for fiscal 2006, implying strong growth.
This growth in revenue, Solomon and Power report, is expected to come through accessing the managed care industry in the US. Currently reimbursement in the US is received for one of the company’s markers.
BRC’s biomarkers have thus far been used in 18 clinical trials and by over 80 different companies and clinicians.
With over $2m of contracts currently in hand, the ABN Amro Morgans team thinks this is one stock “worth keeping an eye on”. There is no recommendation as such as the broker doesn’t cover the stock.

